Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Chronic thromboembolic pulmonary hypertension after pulmonary embolism

Official title: Predictors for Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism Episode

Run by Assiut University · NCT06081881 · Data updated 2026-11-12

This project tests how often people who had an acute pulmonary embolism develop chronic thromboembolic pulmonary hypertension (CTEPH) and which symptoms and echocardiography findings predict it in symptomatic patients.

More Chronic Thromboembolic Pulmonary Hypertension trials

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment100 (estimated)
SponsorAssiut University
Academic / other
Locations1 site (Asyut)
StatusRecruiting
StartedJanuary 1, 2025
Main results expectedOctober 1, 2026
Study endsDecember 1, 2026
Registry record updatedDecember 1, 2025
Trial IDNCT06081881 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 18–80 with a recent acute pulmonary embolism and higher risk by PESI class III–V or sPESI ≥1 who have persistent symptoms are the intended participants.

Probably not a fit

Patients with known secondary causes of pulmonary hypertension, severe kidney or liver impairment, or contraindications to anticoagulation are unlikely to benefit or be eligible for this protocol.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an observational cohort of adults with recent acute pulmonary embolism who meet higher-risk PESI/sPESI criteria, followed to detect incident CTEPH. Participants undergo baseline clinical evaluation and transthoracic Doppler echocardiography with attention to RV function and specific Doppler signs, and are followed for imaging or clinical confirmation of CTEPH. Patients with secondary causes of pulmonary hypertension, severe renal or hepatic impairment, or contraindications to anticoagulation are excluded. The primary goal is to predict CTEPH occurrence in symptomatic post-PE patients using clinical and echocardiographic markers.

Why it matters

Potential benefit: If successful, earlier identification of patients at risk for CTEPH could enable timely referral for potentially curative treatments and reduce long-term disability.

How similar studies have gone: Previous observational cohorts have estimated CTEPH incidence after PE and identified echocardiographic and clinical risk factors, so this approach builds on existing, but still limited, evidence.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Any patient diagnosed as acute pulmonary embolism ,aged between 18-80 years old which Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1,

Exclusion Criteria:

Secondary causes for pulmonary hypertension Severe kidney injury(eGFR\>30 mg/dl/1.7m2) Hepatic affection Contraindication to anti-coagulation

Where it's running

  • Assiut University
    Asyut, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.